Skip to main content
AACR Project GENIE v19.0 · 21,017 myeloid samples Panel-adjusted Fisher's exact with Benjamini-Hochberg FDR N=1 case study · Not clinical guidance

Cross-Database Validation

9 databases reviewed, 4 searched for co-occurrence, zero quintuple matches among 8,655 screened GENIE patients

Databases Searched
4
GENIE (5 variants), cBioPortal and GDC (4 genes), ClinVar
Screened Patients
8,655
GENIE v19.0 myeloid patients with all five genes on panel · HARMONY not queried i
Quintuple Matches Zero
0
5 drivers · 95% bound below 1 in 2,889
Closest GENIE Match
2 of 5
Most exact patient variants in one sample (91 samples); 0 exact triples i

Database Coverage

Zero quintuple matches among 8,655 screened GENIE patients (see the denominator table). GENIE v19.0 provides the statistical backbone (21,017 myeloid samples, 21,017 in the pairwise matrix), supplemented by four-gene searches (EZH2 not included) in cBioPortal (46 studies selected by keyword, including lymphoid and myeloma studies, 25,873 samples) and GDC (24 projects, including solid-tumor projects, 16,411 cases), and by a ClinVar search; ICGC could not be queried. GDC flagged 33 cases as potentially not in GENIE (16 BeatAML, 9 from solid-tumor projects); 3 BeatAML cases carry DNMT3A R882H with an IDH2 mutation, only 1 of them IDH2 R140Q. Additional European and Japanese cohorts (aCML, MDS/MPN overlap cases sequenced under degron-focused or deep-sequencing panels) would extend the analysis into populations not yet represented in these predominantly Western-centric databases.
Database Patients Unique Addition EZH2 V662A Quintuple Result
GENIE v19.017
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
8,655 patients (all 5 genes on panel) Baseline 0 / 20,739 0
cBioPortal (46 studies) 25,873 samples ~5,000 Not searched 0 (4-gene search, no EZH2)
GDC/TCGA (24 projects) 16,411 cases 33 (incl. 9 solid-tumor cases) Not searched 0 (4 exact variants, no EZH2)
IPSS-M (Bernard 2022)13
[13] E 2022
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid (2022)
2,957 ~1,750 N/A N/A
ICGC/PCAWG 1,575 (documented) ~883 (estimate) N/A Not queried (DACO)
Beat AML / Vizome 903 Unknown N/A Via GDC only (4 exact variants)
DepMap (cell lines) 84 84 N/A N/A
ClinVar N/A N/A N/A N/A (no co-occurrence)
Open Targets N/A N/A N/A N/A (gene-drug only)
Cohort sizes are as reported by each source: the GENIE row counts patients with all five target genes (DNMT3A, IDH2, SETBP1, PTPN11, EZH2) on panel; cBioPortal counts samples and GDC cases across every selected study or project. Unique addition figures are rough estimates; no overlap was computed. EZH2 V662A has 0 carriers in GENIE (0 of the 20,739 myeloid samples whose panel covers EZH2). Outside ClinVar, where GeneDx holds a single germline VUS (VCV003373649.1, last evaluated March 2024), the variant does not appear in any public database.

GDC Expanded Results

24 GDC projects queried, 16,411 cases screened.

The GDC expanded search used GRCh38 genomic coordinates for the four exact variants (EZH2 V662A not included). The 24 projects include solid-tumor and mixed projects such as TARGET-NBL, TCGA-SKCM and CPTAC-3. Of 16,411 cases, 33 were flagged as potentially not in GENIE, 9 of them from solid-tumor projects.
Gene Variant Hits Double Matches Notes
DNMT3A 19 3 (with an IDH2 mutation; 1 is R140Q) All doubles in BEATAML (base GDC: 9 SSMs)
IDH2 17 1 (R140Q with DNMT3A R882H) All doubles in BEATAML (base GDC: 2 SSMs)
SETBP1 1 0 Single hit, in CPTAC-3 (solid-tumor project) (base GDC: 0 SSMs)
PTPN11 3 0 No co-occurrence with target genes (base GDC: 3 SSMs)
GDC Data Portal v2 (portal.gdc.cancer.gov). Query: simple somatic mutations across 24 projects (hematological and mixed) using GRCh38 coordinates. March 2026.

cBioPortal Expanded

46 studies, 25,873 samples screened.

Expanded cBioPortal query across studies matched by keyword (myeloid, leukemia, lymphoma, myeloma and others) for DNMT3A, IDH2, SETBP1 and PTPN11 identified 20 patients with mutations in 3 or more of these genes. The closest matches are two patients with IDH2 R140Q and SETBP1 G870S plus a different mutation in a third gene (DNMT3A in one, PTPN11 in the other). Zero four-gene matches were found; EZH2 was not searched.
Metric Value
Studies queried46
Total samples25,873
Patients with 3+ target genes20
Closest match2 patients: IDH2 R140Q + SETBP1 G870S + 1 other gene
Quadruple matches0
Quintuple matchesNot searched (no EZH2)
cBioPortal for Cancer Genomics (cbioportal.org). 46 studies selected by keyword, queried via web API. March 2026.

Genomic Landscape Context

The patient's mutation profile intersects two well-characterized genomic landscapes. Papaemmanuil et al. 12
[12] E 2016
Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med (2016)
classified 1,540 AML patients into 11 genomic classes based on driver co-mutation patterns, including a chromatin-spliceosome class (18% of patients) with poor outcomes. Haferlach et al. 48
[48] T 2014
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2014)
mapped the MDS mutational landscape in 944 patients, with DNMT3A among the genes mutated in more than 10% of cases. SETBP1 mutations 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
2
[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
are recurrent in atypical CML, CMML and secondary AML and carry a poor prognosis.

Quintuple Rarity Context

The original four-gene analysis found 0 matches where 1.13×10-4 were expected among 18,625 samples, a per-sample frequency of 6.1×10-9 (1 in ~165 million). With EZH2 V662A added as a fifth variant (Likely Pathogenic, research classification; ClinVar: VUS), the search becomes a quintuple search. The exact five-variant combination has no estimable population frequency. Zero in 8,655 patients bounds it below 1 in 2,889 (95%, exact binomial). EZH2 V662A has 0 carriers, so every model value for the exact combination depends on the number put in for that zero.

A pairwise maximum-entropy (Ising) model fitted to GENIE predicts mutations in all five genes in about 1 in 25,000 myeloid patients (95% bootstrap interval 1 in 13,000 to 1 in 65,000; sampling error only). The model has one term per gene and one per gene pair, fitted by maximum likelihood to the 8,655 GENIE v19.0 patients 17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
. An earlier version of this section multiplied the 10 pairwise O/E ratios onto the variant frequencies; that product is not a fitted model (a generalised Kirkwood superposition approximation) and was withdrawn as a rarity claim on 2026-11-02.
Scenario Expected Frequency Matches in 250k Patients
Quadruple (DNMT3A+IDH2+SETBP1+PTPN11) 6.1×10-9 ~0.0015
Quintuple (+EZH2 V662A) Not estimable (95% bound below 1 in 2,889) Not estimable
All five genes, any coding variant (fitted Ising model) about 1 in 25,000 ~10
References
  1. AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov (2017). DOI
  2. Bernard E et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid (2022). DOI
  3. Papaemmanuil E et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med (2016). PubMed
  4. Haferlach T et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2014). PubMed
  5. Piazza R et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
  6. Makishima H et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013). PubMed
  7. Canisius S et al. A novel independence test for somatic alterations in cancer. Genome Biol (2016). DOI
  8. Kandoth C et al. Mutational landscape and significance across 12 major cancer types. Nature (2013). PubMed